December 13, 2018:
ERS Genomics Limited and Lonza Pharma & Biotech announced today a license agreement to provide Lonza with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents. Lonza will have the ability to utilize CRISPR/Cas9 in its bioproduction products and services and also for use in induced pluripotent stem cells (iPSC) for research applications.
“Lonza is the world’s leading contract manufacturing organization of biologics and we are thrilled that they have chosen to use CRISPR/Cas9 to enhance their capabilities,” commented Eric Rhodes, CEO of ERS Genomics. “We see tremendous potential for the use of gene editing to enhance the manufacturing of biologics and I expect Lonza will certainly be leading the way.”
Financial details of the agreement were not disclosed.